Every 8-K that Microbot Med Inc (MBOT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBOT filings page.
Microbot Medical Inc. filed its Form 10-Q for the quarter ended June 30, 2026 and reported that second-quarter revenue and customer counts grew by more than 100% versus the first quarter of 2026, driven by repeat orders, expanded utilization and new customer acquisitions following the Full Market Release of its LIBERTY Endovascular Robotic System in mid-April.
The company expanded adoption of LIBERTY across additional hospital sites and U.S. states, broadened its sales footprint from four to eight sales territories, and entered an agreement with Lovell Government Services Inc. to access more than 2,000 government healthcare facilities. It also partnered with Sanmina to establish a second manufacturing site and achieved a key regulatory milestone as Israel granted marketing clearance, the first jurisdiction outside the U.S. to do so. Management highlighted ongoing cost reduction initiatives aimed at substantially lowering cost of revenue.
Microbot Medical Inc. updated the compensation terms for its Chief Financial Officer, Rachel Vaknin, by entering into Addendum #4 to her Employment Agreement. The addendum increases her annual base salary to NIS 864,000, described as the equivalent of $288,000 using a presumed 3:1 NIS-to-U.S. dollar exchange rate. The higher salary is effective as of August 1, 2026. The company characterizes this as a material definitive agreement related to executive employment, and the full terms are set out in the addendum referenced as an exhibit.
Microbot Medical Inc. reports that CEO, President and Chairman Harel Gadot will participate in the Society of Robotic Surgery annual meeting in Fort Lauderdale, Florida, held July 23-26, 2026. He will speak on a “Neurovascular Robotics” panel and present an overview of the endovascular robotic market via livestream.
The company notes recent FDA clearance for its single-use LIBERTY® Endovascular Robotic System, describes growing adoption at leading U.S. academic centers for peripheral endovascular procedures, and highlights winning Surgical Robotics Technology’s Innovative Start-Up Award, which recognizes technologically advanced solutions with potential for broad healthcare impact.
Microbot Medical Inc. reports strong commercial momentum for its LIBERTY Endovascular Robotic System in the second quarter of 2026. The company achieved greater than 100% growth in both revenue and new customers for the quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026, as procedure volume also increased.
This performance follows the Full Market Release of the LIBERTY System on April 13, 2026, with new adoptions by leading health systems in several U.S. states. Microbot also expanded distribution through an agreement with Lovell Government Services to access federal healthcare systems. The company grew its U.S. sales footprint from 4 to 8 territories during the quarter and aims for 12 by year-end, received marketing clearance in Israel as its first market outside the U.S., and agreed to establish a second manufacturing site to support rising demand.
Microbot Medical Inc. has entered into a Letter of Agreement with Sanmina Corporation to manufacture its LIBERTY® Endovascular Robotic System. Sanmina will serve as an additional manufacturing site, giving Microbot more capacity to meet expected demand from existing and new customer accounts.
The company states that expanding manufacturing with a global contract manufacturer is part of its cost reduction strategy. It expects the arrangement to improve operating efficiencies, lower costs, and support higher gross margins as LIBERTY adoption grows in the U.S. and internationally, including Israel and markets where it is pursuing CE Mark and other registrations.
Microbot Medical Inc. filed a current report noting that it has won the Innovative Start-Up Award from Surgical Robotics Technology for its LIBERTY® Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
The company reports continued adoption and increased use of LIBERTY following its Full Market Release in early April, including use at leading academic centers across several U.S. states. Management and SRT highlight the system’s innovative design, potential broad healthcare impact, and its aim to improve precision, efficiency, and safety in endovascular care.
Microbot Medical Inc. filed a current report describing new commercial progress for its LIBERTY® Endovascular Robotic System. A globally recognized academic center headquartered in Pennsylvania became the first health system in that state to adopt LIBERTY, joining existing customers in New York City and Boston.
The new customer operates multiple hospitals and multispecialty centers across Pennsylvania and New Jersey, and is the company’s second customer with facilities spanning two states. Microbot now has accounts in seven Eastern U.S. states and, following its recent full market release, plans to expand its sales footprint to the West Coast and further into international markets. A recent agreement expanding access to LIBERTY across certain U.S. federal healthcare systems, including veterans and military patient populations, is also highlighted.
Microbot Medical Inc. has entered into a vendor agreement with Lovell Government Services, creating an opportunity to sell its LIBERTY® Endovascular Robotic System at more than 2,000 U.S. government healthcare facilities, including those of the VA, Department of Defense and Indian Health Service.
Lovell, a Service-Disabled Veteran-Owned Small Business, will list the LIBERTY System on its Federal Supply Schedule contract, with activation expected during the third quarter of 2026, and make it available through platforms such as GSA Advantage, ECAT and DAPA. The relationship is intended to streamline procurement and support broader awareness and adoption across federal healthcare systems.
Microbot Medical Inc. announced that one of the largest healthcare systems in Michigan has become its first Midwest-based account to adopt the LIBERTY Endovascular Robotic System. This follows its first healthcare system customer in North Carolina, showing broader regional uptake across key U.S. markets.
LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, targeting a U.S. market of approximately 2.5 million procedures annually. The system also recently received regulatory approval in Israel, allowing marketing and sales there as the company advances its full market release strategy.
Microbot Medical Inc. reported a commercial update highlighting new adoption of its LIBERTY® Endovascular Robotic System. The company secured its first North Carolina-based healthcare system customer, described as a leading academic center with a multi-hospital network covering the state.
This new account expands LIBERTY’s geographic footprint from the southeast and mid-Atlantic into the broader northeast and South-Atlantic regions, aligning with Microbot’s commercial strategy following the system’s full market release. The report and accompanying press release also include standard cautionary language about forward-looking statements and refer readers to existing SEC filings for detailed risk factors.
Microbot Medical Inc. reported that Israel’s Ministry of Health AMAR Division has granted regulatory approval for its LIBERTY® Endovascular Robotic System. This approval allows the company to market and commercialize LIBERTY in Israel and obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions.
Israel is the second jurisdiction, and the first outside the U.S., to grant marketing clearance for LIBERTY. The company is also pursuing CE Mark certification and working toward completion by the end of 2026 to support a planned next phase of commercial expansion into the EU market, while the U.S. remains its primary focus.
Microbot Medical Inc. filed a current report describing plans for an analysts and investors conference call and webcast. The call will be held on Monday, May 18 at 3:00pm ET to review recent progress of the Full Market Release of its LIBERTY Endovascular Robotic System and to address company and product information it says was misrepresented in a recent unaffiliated third-party article. Management, along with two current LIBERTY users, Dr. Charles Briggs and Dr. Zachary Bercu, will discuss real-world experience with the system and respond to described inaccuracies. Access details are available via the company’s investor relations website and a teleconference registration link.
Microbot Medical Inc. reports its first revenue from the LIBERTY® Endovascular Robotic System during the fiscal quarter ended March 31, 2026, driven by a Limited Market Release. Early in the following quarter, the company began a Full Market Release.
By mid-second quarter 2026, revenue from LIBERTY had already exceeded total first quarter revenue, supported by more than doubling the number of accounts since the end of the limited release. Hospitals in six states, including Georgia, Florida, New York, Michigan, Massachusetts and North Carolina, are using the system, with Boston becoming the first city with multiple accounts.
The company highlights growing recurring orders, new accounts and a larger pipeline, as well as procedures that include what it believes is the world’s first robotic Prostatic Artery Embolization and other complex interventions. Updated occupational safety guidelines and visibility at major conferences are described as supportive of further U.S. and global commercial expansion.
Microbot Medical Inc. filed a current report describing commercial progress for its LIBERTY Endovascular Robotic System. Following the Full Market Release at the Society of Interventional Radiology annual meeting, the company reports strong interest from physicians and hospital executives and has already won multiple accounts in key sales territories.
The new accounts include two sites that previously participated in the ACCESS-PVI pivotal clinical trial, which the company highlights as validation that trial users see value in adopting LIBERTY for everyday practice. Microbot plans to further showcase LIBERTY at the Global Embolization Symposium & Technologies conference in New York in mid-May and is expanding its international commercial infrastructure, including a new Vice President of Sales for EMEA.
Microbot Medical Inc. is expanding its commercial strategy by appointing Alon Tamir as Vice President of Sales for Europe, the Middle East and Asia (EMEA) to lead regional sales and partnerships for its LIBERTY Endovascular Robotic System.
The company will keep prioritizing the U.S. market, where LIBERTY has completed a Limited Market Release and moved into Full Market Release following U.S. Food and Drug Administration clearance in September 2025. Management views EMEA as a major opportunity, noting Europe alone has an estimated 2.3 million peripheral endovascular procedures annually, and the company anticipates obtaining CE mark approval by the end of 2026.
Microbot Medical Inc. furnished an update describing how new occupational protection guidelines from the Society of Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe may support the commercial position of its LIBERTY® Endovascular Robotic System.
The guidelines focus on reducing radiation exposure and musculoskeletal strain for interventional radiology staff, including new recommendations for pregnancy protection. Microbot highlights LIBERTY’s remote, seated operation as a potential way to address radiation, ergonomics and staffing challenges, and notes that multiple U.S. and European medical societies, as well as the American Medical Association, are emphasizing stronger radiation-safety practices.
Microbot Medical Inc. filed an 8-K noting it will showcase recent commercial achievements that led to the Full Market Release (FMR) of its LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference.
CEO Harel Gadot and senior executives will present live at 10:15 a.m. ET on April 15, 2026, discussing the company’s strategy, growth opportunities, and how LIBERTY aims to address physician radiation exposure, physical strain, and staffing issues. The presentation will be webcast via the company’s investor website, and management will also hold one-on-one meetings with healthcare-focused institutional investors.
The press release describing these plans is furnished as an exhibit and includes standard forward-looking statements language.
Microbot Medical Inc. is moving from a limited to a full U.S. market release of its LIBERTY® Endovascular Robotic System. The full launch is scheduled to coincide with the Society of Interventional Radiology Annual Scientific Meeting in Toronto, which brings together its primary U.S. target users.
LIBERTY, described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, has already been adopted by multiple healthcare systems, including hospitals such as Emory Healthcare and Tampa General Hospital. It has been used commercially in procedures like Prostate Artery Embolization, Uterine Fibroid Embolization, Genicular Artery Embolization, Y90 mapping and deliveries, and peripheral arterial interventions.
To support the full market release, the company has expanded its commercial organization, increasing its U.S. sales footprint from four to eight territories and setting a goal of 12 territories by the end of 2026. Management highlights physician feedback on LIBERTY’s precision, short learning curve, fast setup and the ability to use preferred wires and catheters, while also pointing to industry moves to strengthen protections against occupational radiation exposure as a supportive backdrop for remotely operated systems.
Microbot Medical Inc. is activating its existing at-the-market equity program with H.C. Wainwright & Co. Under this arrangement, the company may sell shares of its common stock, par value $0.01 per share, from time to time up to an aggregate offering price of $39,230,691.
Sales can occur on the Nasdaq Capital Market, through market makers, or directly to Wainwright in negotiated transactions at prevailing market prices or prices related to them. These sales will be made under a shelf registration statement on Form S-3, using a prospectus and a new prospectus supplement filed with the SEC. The company also filed a legal opinion from its counsel on the validity of the shares.
Microbot Medical Inc. filed an update highlighting real-world use of its LIBERTY Endovascular Robotic System at Emory Healthcare. Emory’s interventional radiologists successfully performed robotic peripheral endovascular procedures, including the world’s first robotic prostatic artery embolization for benign prostatic hyperplasia and robotic Y-90 radioembolization mapping for liver cancer.
The LIBERTY System is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision, reduce radiation exposure and physical strain, and improve procedural efficiency. Microbot began a Limited Market Release in November 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026 to further drive adoption.
Microbot Medical Inc. reported that a pivotal clinical study of its LIBERTY® Endovascular Robotic System has been published in the peer‑reviewed Journal of Vascular and Interventional Radiology. The article analyzes the ACCESS-PVI multicenter feasibility study, whose lead principal investigator was Dr. Francois Cornelis.
The company notes that publication follows completion of the ACCESS-PVI study in 2025 and its presentation at the Society of Interventional Radiology meeting. LIBERTY received U.S. FDA clearance in September 2025 for peripheral endovascular procedures. Microbot began a limited market release in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. furnished an 8-K to share that it will participate in the Roth Annual Growth Conference in Laguna Niguel, California from March 22-24, 2026. CEO Harel Gadot will join a live fireside Q&A on March 23, with a webcast available through the company’s website.
The company also released updated investor presentation materials, accessible online, highlighting progress with its LIBERTY Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, moving from a limited market release that began in late 2025 toward a planned full market release at the SIR conference in April 2026.
Microbot Medical Inc. filed a report to share that it will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16–19, 2026. CEO, President and Chairman Harel Gadot will present live at 8:40 a.m. ET on March 19, 2026.
The company will highlight the expanding clinical experience and recent achievements from the limited market release of its LIBERTY Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot began a limited market release in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. filed a current report describing a press release about its LIBERTY® Endovascular Robotic System and recent policy from the American Medical Association on occupational radiation exposure. The AMA adopted a policy in late 2025 to strengthen protections for health care professionals and trainees exposed to ionizing radiation.
Microbot emphasizes that LIBERTY is remotely operated and, in the ACCESS-PVI Study, use of the system showed a 92% relative reduction in radiation exposure. The company began a Limited Market Release of LIBERTY in late 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. reported that its operations and commercial activities remain stable despite current geopolitical events in the Middle East. The company states there is no business disruption in either the U.S. or Israel, and that employee safety and security remain a top priority.
Following recent FDA clearance of its LIBERTY Endovascular Robotic System, Microbot is focusing commercialization on the U.S. market using a dedicated commercial team based in Hingham, Massachusetts. The company indicates internal operations and its lead manufacturing partner are fully functional, with sufficient U.S. inventory and additional stock being built through a third-party logistics partner.
Microbot is preparing for a full market release of the LIBERTY System at the Society of Interventional Radiology conference in April 2026, after beginning a limited market release in late 2025. To support expansion, it has hired additional U.S. sales representatives and a Director of Health Economics and Outcomes Research, while continuing to monitor Middle East developments to maintain uninterrupted customer support.
Microbot Medical Inc. reported changes to its executive employment arrangements and a one-time cash award. As of February 20, 2026, the company entered into an addendum to the employment agreement with Simon Sharon, an addendum with Rachel Vaknin, and an amendment to the employment agreement with Juan Diaz-Cartelle. On February 18, 2026, the board also authorized a special bonus of approximately $140,000 for CEO, President and Chairman Harel Gadot, which is in addition to bonuses he may receive under his existing employment agreement.
Microbot Medical reported that Tampa General Hospital has become the first health system in Florida to adopt its LIBERTY® Endovascular Robotic System, following recent FDA 510(k) clearance. The company sees this as early post-clearance momentum in a U.S. peripheral endovascular market of about 2.5 million procedures annually.
Microbot began a limited market release of LIBERTY in late 2025 and plans a full commercial launch at the Society of Interventional Radiology conference in April 2026. LIBERTY is described as a single-use, remotely operated robotic system designed to improve precision and reduce radiation exposure and physical strain during peripheral endovascular procedures.
Microbot Medical Inc. filed an 8-K to share that CEO, President and Chairman Harel Gadot will be a featured panelist at The Surgical Disruptive Technology Summit during the SAGES NBT Innovation Weekend in Houston. He will join a session on endovascular therapeutics, AI and robotics.
The company uses this event to spotlight its LIBERTY Endovascular Robotic System, described as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot began a limited market release of LIBERTY in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. filed a report describing a press release about its LIBERTY® Endovascular Robotic System being highlighted at the International Symposium on Endovascular Therapy conference in Miami Beach, Florida.
The company notes that LIBERTY, described as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, was prominently discussed in a town hall session on advances in endovascular robotics. Management states that LIBERTY is in a limited market release that began in late 2025 and that a full market release is planned at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. filed a report stating that it is attending the Society of Interventional Oncology annual meeting in Savannah, Georgia, held February 4–8, 2026. The timing coincides with the company’s limited market release of its LIBERTY Endovascular Robotic System.
During the meeting, Microbot plans to share practical insights and personal experiences from physicians who have used LIBERTY across different hospitals and procedure types. The company furnished, but did not file, a related press release as Exhibit 99.1 under Regulation FD.
Microbot Medical Inc. filed a current report to share that it issued a press release on January 12, 2026. The release reaffirms the company’s achievements in 2025 and announces key anticipated milestones for 2026, highlighting its recent progress and future business, regulatory, or financial targets. The press release is furnished as Exhibit 99.1 and incorporated by reference, and the company includes customary cautionary language that statements about expected future milestones are forward-looking and subject to various risks and uncertainties.
Microbot Medical Inc. reported that Emory University Hospital in Atlanta has become the first hospital in the world to adopt its LIBERTY® Endovascular Robotic System for patient care. This marks the system’s transition from development and evaluation into real-world clinical use at a major academic medical center.
The company is also collaborating with Emory to establish an Endovascular Robotics Program within interventional radiology. This collaboration is intended to integrate robotic technology into clinical workflows and may help build clinical experience and visibility for the LIBERTY system over time.
Microbot Medical (MBOT) announced U.S. commercial availability of its LIBERTY Endovascular Robotic System on a limited basis. The company is initiating a limited market release to selected high procedure volume regions where it has already experienced preliminary demand.
The update was shared via a press release furnished under Regulation FD and listed as Exhibit 99.1. This marks an initial commercialization step intended to introduce LIBERTY to targeted centers in the United States.
Microbot Medical (MBOT) reported it will exhibit its LIBERTY® Endovascular Robotic System at the Symposium on Clinical Interventional Oncology in Miami, FL on October 17–19, 2025. This marks the first medical meeting where the company will commercially exhibit the LIBERTY® System following its FDA 510(k) clearance.
The company also announced it has recently completed the hiring and on‑boarding of its commercial leadership team. The disclosure was furnished under Regulation FD.
Microbot Medical announced a partnership with a U.S.-based third-party logistics provider to support commercialization of its FDA-cleared LIBERTY Endovascular Robotic System. The company plans a limited market release in the fourth quarter of 2025, followed by a broader launch in April 2026 aligned with the Society of Interventional Radiology conference.
The disclosure was furnished under Regulation FD and as an Other Event, with a related press release included as Exhibit 99.1.
Microbot Medical Inc. reports that on October 6, 2025, a holder exercised 1,324,488 existing series H preferred investment options for 1,324,488 shares of common stock at an exercise price of $2.10 per share. Under a previously disclosed inducement letter agreement, the holder also received 1,324,488 new series J preferred investment options.
This transaction represents the third and final closing under that inducement arrangement, which was required to occur on or before October 15, 2025. Microbot also issued 66,224 preferred investment options to H.C. Wainwright & Co., LLC under a May 29, 2024 engagement letter, as amended.
The new preferred investment options and the Wainwright preferred investment options, and the shares underlying them, were issued as unregistered securities in reliance on Section 4(a)(2) of the Securities Act and may be resold only pursuant to registration or an applicable exemption. Shares issuable upon exercise of the existing options are already registered under a post-effective amendment to a Form S-1 registration statement. The company also noted it issued a press release on October 7, 2025 announcing this third closing.
Microbot Medical Inc. reported several recent equity transactions involving preferred investment options and common stock. On September 29, 2025, a holder exercised 600,000 series H preferred investment options for 600,000 shares of common stock at an exercise price of $2.10 per share and, under a prior inducement letter, received 600,000 new series J preferred investment options. The company also issued 30,000 preferred investment options to H.C. Wainwright & Co., LLC under an existing engagement letter, all in unregistered transactions relying on Section 4(a)(2) of the Securities Act.
Separately, on September 23, 2025, Microbot issued 374,167 shares of common stock upon exercise of an equal number of preferred investment options at exercise prices between $1.875 and $2.6625, generating approximately $896,000 in gross proceeds before fees. The resale of shares issuable from the previously issued series H options is covered by an effective registration statement, while the new options and their underlying shares remain unregistered and subject to resale restrictions.
Microbot Medical Inc. reported that the Japanese Patent Office has granted the company its first patent in Japan covering the core LIBERTY® System technology.
The patent relates to a compact robotic device used to drive and control the movement of at least one long surgical tool, supporting the company’s robotic surgery platform. The company also furnished a press release with the same information as an exhibit to the report.
Microbot Medical Inc. filed a current report to share that its Chief Executive Officer, Harel Gadot, will appear on Benzinga All Access at 10:45 a.m. ET on Wednesday, September 24, 2025. During the interview, he is expected to discuss the recent FDA clearance of the Company’s LIBERTY® system and how the Company has planned for its commercialization in the United States.
The Company furnished a related press release as Exhibit 99.1, and this communication is being treated as “furnished” rather than “filed” under securities laws. The filing highlights ongoing communication with the market about Microbot Medical’s efforts to redefine the peripheral endovascular space with its LIBERTY® technology.
Microbot Medical Inc. disclosed that its board’s Compensation Committee approved special one-time cash bonuses for several executives and non‑management directors. CEO, President and Chairman Harel Gadot received $158,115, CTO Simon Sharon received approximately $64,200, and executive officer Rachel Vaknin received approximately $32,500. The committee also authorized one-time cash payments of $30,000 to $45,000 for each non‑management board member.
The committee noted that these payments reflect, in part, that the executives had previously waived 30–50% of their prorated 2023 base salaries under the company’s May 2023 cost restructuring plan.
Microbot Medical Inc. entered into an inducement agreement with certain holders of its existing preferred investment options, who agreed to exercise options to buy up to 13,989,115 shares of common stock for cash in exchange for new Series J preferred investment options to buy up to 13,989,115 shares at an exercise price of $4.50 per share. At a first closing, holders exercised options for up to 12,064,627 shares, generating approximately $25.2 million in gross proceeds, and a second closing is expected to add exercises for up to 1,924,488 shares for approximately $4.0 million in gross proceeds.
The company plans to use the net proceeds to advance development, commercialization and regulatory activities for its LIBERTY® Robotic System, pursue potential acquisitions, expand applications from its IP portfolio, and for working capital and general corporate purposes. Microbot also issued unregistered new options to investors and to H.C. Wainwright & Co., which served as exclusive placement agent and will receive cash fees, expense reimbursements, and additional preferred investment options tied to current and future cash exercises.
Microbot Medical Inc. furnished an update under Regulation FD by making new investor presentation materials available on its website. The slides can be accessed through the ‘Investors’ section under ‘IR Resources’ and then ‘Additional Resources.’
The company also highlighted its participation in the H.C. Wainwright Annual Investor Conference in New York, where President, CEO and Chairman Harel Gadot is scheduled to present on September 9, 2025, with a live webcast available through the ‘Events’ section of the website. The presentation materials are furnished as Exhibit 99.1 to this report and are expressly described as furnished, not filed, which limits their treatment under certain securities law liability provisions.
Microbot Medical Inc. filed an 8-K to report that the U.S. Food and Drug Administration has granted 510(k) clearance for its LIBERTY® Endovascular Robotic System, described as the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. This clearance allows the company to move ahead with final commercial activities that depended on marketing clearance and to begin U.S. commercialization, with an aim to address approximately 2.5 million annual U.S. peripheral vascular procedures and later pursue global markets. The company also disclosed that its President, CEO and Chairman, Harel Gadot, is presenting at the H.C. Wainwright Annual Investor Conference in New York on September 9, 2025, with a live webcast available via its website.
Microbot Medical Inc. reported that from August 26 to August 27, 2025 it issued 4,055,870 new shares of common stock through the exercise of previously issued preferred investment options. Holders exercised 300,000 Series H options at $2.10 per share and 3,755,870 Series I options at $2.13 per share, providing the company with approximately $8.6 million in gross cash proceeds before fees and expenses. As of August 27, 2025, Microbot Medical had about 52,569,762 common shares outstanding. The company relied on a private offering exemption under Section 4(a)(2), while the shares underlying both the Series H and Series I options had already been registered for resale on prior Form S-3 registration statements.
Microbot Medical Inc. reported unregistered sales of its common stock tied to option exercises. From August 11 to August 25, 2025, the company issued an aggregate of 2,967,953 shares of common stock upon the exercise of outstanding Series E, Series G, and Series H preferred investment options at exercise prices of $1.50, $1.75, and $2.10 per share, respectively, generating approximately $5.9 million in gross proceeds before fees and expenses. Microbot also issued 47,218 shares of common stock upon the exercise of incentive options by a former director. As of August 25, 2025, the company had approximately 48,513,892 shares of common stock issued and outstanding. The shares were issued as private transactions under Section 4(a)(2) of the Securities Act, and the shares underlying the preferred investment options had been previously registered for resale on Form S-3 registration statements.
Microbot Medical Inc. reported that the U.S. Patent and Trademark Office has granted it a patent covering a modular robotic surgical system with a base and multiple independently attachable tool-receiver units. The company explains that this patent may allow its LIBERTY device to be adapted over time for a wider range of endovascular procedures, which could substantially increase the total addressable market it seeks to reach. The patent also broadens Microbot’s intellectual property protection for the LIBERTY system portfolio, which now consists of 12 patents granted globally and 57 patent applications pending.